<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00521664</url>
  </required_header>
  <id_info>
    <org_study_id>PEI 1224/01</org_study_id>
    <nct_id>NCT00521664</nct_id>
  </id_info>
  <brief_title>A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups</brief_title>
  <official_title>Prospective Randomized Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups: 1)in Patients With Acute Myeloid Leukemia After Intensive Chemotherapy and 2) After Autologous Blood Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show that a therapeutic platelet transfusion strategy (i.e.
      platelet transfusion only in case of bleeding) needs minimally a quarter less of transfusions
      compared to the standard prophylactic transfusion strategy (i.e. platelet transfusion without
      any sign of bleeding when the platelet count is below 10.000/µL). With the experimental
      transfusion strategy transfusions could be safely reduced when the study hypothesis can be
      proven. This is the first prospective randomized study on this topic.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction in numbers of platelet transfusion by 25 % in the experimental arm (therapeutic transfusion strategy)compared with the standard arm (prophylactic transfusion strategy)</measure>
    <time_frame>2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>- incidence and duration of clinically relevant bleeding - numbers of red blood cell transfusion - side effects of transfusions - duration of thrombocytopenia below 10.000/µL and below 20.000/µL - duration of hospitalisation</measure>
    <time_frame>2010</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Therapeutic platelet transfusion (TP) strategy versus prophylactic platelet transfusion (PP) strategy. In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prophylactic platelet transfusion</intervention_name>
    <description>In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Therapeutic platelet transfusion</intervention_name>
    <description>In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        AML project

          -  inclusion in studies of the DSIL or OSHO group for AML

          -  AML M3/M3v can be included only when in complete remission

          -  age 16 - 80 years

          -  written informed consent

        Autologous project

          -  AMl and ALL patients in first or second remission

          -  low grade or high grade non hodgkin lymphoma or morbus hodgkin or multiple myeloma

          -  conditioning regime: TBI 8-12 Gy/Cy 120 or BEAM or BU/CY or Melphalan 140-200mg/m2 or
             a similarly intensive chemotherapy regime

          -  age 16 - 65 years

        Exclusion Criteria:

        AML project

          -  known refractoriness to platelet transfusion

          -  known major bleeding with thrombocytopenia when the reason for bleeding is still
             ongoing

          -  known plasmatic coagulation disorder

          -  patient unable to give informed consent

        Autologous project

          -  known refractoriness to platelet transfusion

          -  known major bleeding with thrombocytopenia when the reason for bleeding is still
             ongoing

          -  known plasmatic coagulation disorder

          -  patient unable to give informed consent

          -  patients with pulmonal or cerebral lesions due to infection or neoplasm

          -  patients with al-amyloidosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Ehninger, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Carl Gustav Carus Dresden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord; Einheit für Knochenmarktransplantation; 5. Med. Klinik</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.pubmedcentral.nih.gov/</url>
  </link>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2007</study_first_submitted>
  <study_first_submitted_qc>August 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2007</study_first_posted>
  <last_update_submitted>May 18, 2011</last_update_submitted>
  <last_update_submitted_qc>May 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Katrin Peschel</name_title>
    <organization>Dresden University of Technology</organization>
  </responsible_party>
  <keyword>proof of safety and cost effectiveness of the new therapeutic platelet transfusion strategy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

